Difference between revisions of "File:Fig2 Smith PracLabMed2024 InPress.jpg"

Latest revision as of 20:06, 26 May 2024

Description	Figure 2. Responses to survey questions. Respondents were asked (a) whether they support the FDA proposal to regulate LDTs, (b) whether they perform LDTs within their laboratories, (c) if their laboratories would be negatively impacted by the proposed rule if enacted, (d) if they anticipate having to remove tests from their laboratory menus if the proposed rule is enacted, and (e) whether they have the financial resources to pay for FDA user fees. Questions for (c), (d), and (e) were asked only of respondents whose laboratories performed LDTs.
Source	Smith, Leslie; Carricaburu, Lisa A.; Genzen, Jonathan R. (2024). "The US FDA’s proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing". Practical Laboratory Medicine In press: e00407. doi:10.1016/j.plabm.2024.e00407.
Date	2024
Author	Smith, Leslie; Carricaburu, Lisa A.; Genzen, Jonathan R.
Permission (Reusing this file)	Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
Other versions

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Click on a date/time to view the file as it appeared at that time.

	Date/Time	Thumbnail	Dimensions	User	Comment
current	19:41, 26 May 2024		2,764 × 3,728 (450 KB)	Shawndouglas (talk \| contribs)

You cannot overwrite this file.

The following page uses this file:

This file contains additional information, probably added from the digital camera or scanner used to create or digitize it.

If the file has been modified from its original state, some details may not fully reflect the modified file.

JPEG file comment	HiRes

@@ Line 1: / Line 1: @@
+==Summary==
+{{Information
+|Description='''Figure 2.''' Responses to survey questions. Respondents were asked ('''a''') whether they support the FDA proposal to regulate LDTs, ('''b''') whether they perform LDTs within their laboratories, ('''c''') if their laboratories would be negatively impacted by the proposed rule if enacted, ('''d''') if they anticipate having to remove tests from their laboratory menus if the proposed rule is enacted, and ('''e''') whether they have the financial resources to pay for FDA user fees. Questions for ('''c'''), ('''d'''), and ('''e''') were asked only of respondents whose laboratories performed LDTs.
+|Source={{cite journal |title=The US FDA’s proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing |journal=Practical Laboratory Medicine |author=Smith, Leslie; Carricaburu, Lisa A.; Genzen, Jonathan R. |volume=In press |at=e00407 |year=2024 |doi=10.1016/j.plabm.2024.e00407}}
+|Author=Smith, Leslie; Carricaburu, Lisa A.; Genzen, Jonathan R.
+|Date=2024
+|Permission=[http://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International]
+}}
 == Licensing ==
 {{cc-by-nc-nd-4.0}}